https://www.selleckchem.com/products/apd334.html
ove the coincidence rate and accuracy of early diagnosis of lung cancer, shorten the average detection time, and provide more accurate information for clinical decision-making. To study and analyze the clinical efficacy of axitinib combined with tislelizumab in the treatment of advanced renal cell carcinoma and its effects on renal function and serum cytokines. Totally 49 patients with advanced renal cancer treated in our hospital from November 2018 to January 2020 were randomized to treatment with axitinib (control group, = 27) or axit
Aimer
Commentaire
Partagez
